Compare TG Therapeutics Inc (TGTX) vs Western Alliance Bancorporation (WAL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
TG Therapeutics Inc vs Western Alliance Bancorporation — how do they compare? TG Therapeutics Inc trades at $49.44 (market cap $7.64B), while Western Alliance Bancorporation trades at $82.6 (market cap $8.89B). The key difference: Western Alliance Bancorporation is the larger of the two by market cap, and Western Alliance Bancorporation pays a 2.06% dividend while TG Therapeutics Inc pays none. Which is the better fit depends on your goals.
| TGTX | WAL | |
|---|---|---|
Market Cap | $7.64B | $8.89B |
Sector | Health | Financials |
52-Week High | $59.06 | $96.08 |
52-Week Low | $26.94 | $66.70 |
Enterprise Value | $7.84B | — |
Dividend Yield | — | 2.06% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
TG Therapeutics (TGTX) trades at $49.50, up 0.69% today, with a bearish technical signal from moving averages despite neutral oscillators. The company reported strong revenue growth, with Q2 2026 sales reaching $240 million and raised full-year guidance to $950 million, though it missed earnings estimates for three consecutive quarters. Profitability metrics remain robust with a net income margin of 55.22% and ROE exceeding 100%, but valuation ratios like EV/EBITDA at 56.26 suggest premium pricing.
The outlook is mixed: bullish analyst sentiment with an 84.6% buy rating and a $63.75 price target offers upside potential, driven by Briumvi's commercial success and expansion into schizophrenia trials. However, risks include earnings misses, a shareholder investigation into fiduciary duties, and high cash burn in 2025. Investors should weigh strong revenue momentum against execution risks and elevated valuations.
Western Alliance Bancorporation (WAL) trades at $82.62, up 2.66% today, with a neutral technical signal and bullish analyst sentiment. The stock shows strong fundamentals with a P/E of 9.2, net income margin of 25.43%, and recent earnings beats in Q4 2025 and Q1 2026. Recent developments include the launch of WA VenueX, a financial platform for digital assets, and recognition as Arizona's #1 bank by Forbes in 2026.
Outlook remains positive with a consensus price target of $93.86, implying 13.6% upside, supported by revenue growth and profitability. Risks include reliance on net interest income, competitive pressures, and macroeconomic sensitivity. Institutional activity shows mixed signals with some trimming positions, but overall analyst consensus is strongly bullish with 79% buy ratings.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About TG Therapeutics Inc
TG Therapeutics is a fully integrated biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases. Its cornerstone product, BRIUMVI (ublituximab-xiiy), is a glycoengineered monoclonal antibody approved for relapsing forms of multiple sclerosis. The company is currently executing a 'pipeline-in-a-product' strategy, expanding BRIUMVI into new delivery methods and indications while advancing a broader portfolio of autoimmune and oncology candidates.
Read more on TGTX →About Western Alliance Bancorporation
Western Alliance Bancorporation is a top-performing bank holding company that operates a dual business model: high-touch regional banking and specialized national business lines. It serves niche industries—including technology, life sciences, and homeowners associations—providing sophisticated commercial lending and treasury solutions that bridge the gap between regional service and national scale.
Read more on WAL →
